Liver cancer risk study for people with fatty liver disease
Part of Cancer, Genetic & congenital, Hormones & metabolism clinical trials.
This study looks at your risk of developing liver cancer (hepatocellular carcinoma) if you have a liver condition such as NAFLD or a related disease. It aims to improve how doctors predict who might be at higher risk, so they can offer better monitoring and care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 45 and 75 years old.
- You have nonalcoholic fatty liver disease (NAFLD) or a liver disease of unknown cause, and you may have some alcohol intake (up to 60/40 grams per day for men/women).
- You have moderate to severe liver scarring (F3-F4 fibrosis), cirrhosis, or a family history of liver cancer, or you are a man with diabetes or obesity and certain genetic variants.
- You are willing to sign a consent form to take part in the study.
- You do not have a history of hepatitis B or C, autoimmune hepatitis, or other genetic liver conditions like hemochromatosis or Wilson's disease.
- You have not been diagnosed with liver cancer before the study starts, and you do not have another serious illness that would limit your life to less than 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your genes and alcohol use together affect the risk of liver cancer. It may help find ways to prevent cancer in people with fatty liver disease or moderate alcohol intake.
This study aims to find a simple way to detect liver fibrosis, a condition where the liver becomes scarred, in people who have risk factors like being overweight, having type 2 diabetes, or drinking alcohol heavily. By identifying fibrosis early, it may help prevent more serious liver problems.
This study is looking at how well antiviral treatments work to prevent liver cancer in people with chronic hepatitis B who have a family history of the disease. If you are over 30 and taking antiviral medication, you may be able to join.
This trial tests a new blood test to help detect liver cancer (HCC) or confirm it’s not present in people with cirrhosis who are being monitored. It may help improve how doctors screen for liver cancer and decide who needs further imaging or treatment.
This study collects information about metabolic and unexplained (cryptogenic) liver disease and looks at “omics” tests, which are lab tests that measure patterns in blood or tissue to learn what drives the disease. It may help researchers better understand fatty liver and related serious complications, like liver scarring and liver cancer.
This study aims to predict the risk of developing liver cancer in people with chronic liver conditions such as hepatitis B or C, cirrhosis, or fatty liver disease. By participating, you may help researchers improve early detection and prevention strategies for liver cancer.
Hear when a new Genetic Predisposition trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.